Company
Chimeric Therapeutics Ltd
ASX:CHM
Chimeric Therapeutics Ltd, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. The company's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of today's most innovative solutions, and has shown a consistent ability to deliver on its objectives.
83 stories · page 1 of 5
Chimeric Therapeutics presents CHM 1101 Phase 1B clinical trial at ASCO annual scientific meeting
The ASCO abstract provided additional background data on one patient from the initial dose cohort that achieved survival of 15.5 months from time of 1st CHM 1101 infusion.
Chimeric Therapeutics in exclusive licence agreement with Case Western Reserve University for CORE-NK Platform
The CORE-NK platform uses a novel, proprietary genetically modified feeder cell line to activate and expand universal off-the-shelf allogeneic NK cell products derived from healthy donors.